Harvard Apparatus Regenerative Technology, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
HRGNStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2026 | 2025 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(1,601) | $(1,659) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 632 | 485 |
| Depreciation | 1 | 2 |
| Amortization of operating lease right-of-use assets | 27 | 23 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | — | 227 |
| Inventory | 1 | 32 |
| Prepaid expenses and other current assets | 22 | (85) |
| Long-term prepaid contracts | (105) | 70 |
| Accounts payable | (215) | 3 |
| Operating lease liability | (26) | (22) |
| Accrued and other current liabilities | 307 | (38) |
| Deferred revenue | 88 | 299 |
| Insurance premium financing payable | (68) | (95) |
| Net cash used in operating activities | (937) | (758) |
| Effect of exchange rate changes on cash | 4 | — |
| Net decrease in cash and cash equivalents | (933) | (758) |
| Cash and cash equivalents at the beginning of the year | 1,352 | 2,486 |
| Cash and cash equivalents at the end of the period | $419 | $1,728 |
| SUPPLEMENTAL INFORMATION | ||
| Interest paid in cash | $2 | $2 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.